298 related articles for article (PubMed ID: 29969801)
1. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.
Kuraoka N; Hara K; Terai S; Yatabe Y; Horio Y
Endoscopy; 2018 Sep; 50(9):E259-E261. PubMed ID: 29969801
[No Abstract] [Full Text] [Related]
2. Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports.
Onoyama T; Takeda Y; Kato M; Edano M; Tarumoto R; Matsumoto K; Isomoto H
Endoscopy; 2019 Dec; 51(12):E402-E403. PubMed ID: 31340390
[No Abstract] [Full Text] [Related]
3. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
[No Abstract] [Full Text] [Related]
4. Endoscopic ultrasound-guided gallbladder drainage to facilitate biliary rendezvous for the management of cholangitis due to choledocholithiasis.
Law R; Baron TH
Endoscopy; 2017 Dec; 49(12):E309-E310. PubMed ID: 28992637
[No Abstract] [Full Text] [Related]
5. Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.
Hamoir C; de Vos M; Clinckart F; Nicaise G; Komuta M; Lanthier N
J Gastroenterol Hepatol; 2018 Oct; 33(10):1695. PubMed ID: 29707809
[No Abstract] [Full Text] [Related]
6. [Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.].
Cortinovis DL
Recenti Prog Med; 2018 Mar; 109(3):197e-201e. PubMed ID: 29565054
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
Mazzaschi G; Bordi P; Fioretzaki R; Gnetti L; Milanese G; Tommasi C; Bersanelli M; Roti G; Scoditti U; Leonardi F; Quaini F; Tiseo M
Clin Lung Cancer; 2020 Mar; 21(2):e65-e73. PubMed ID: 31837925
[No Abstract] [Full Text] [Related]
9. Inflammatory Bowel Disease in an Elderly Woman After Nivolumab Administration.
Abe K; Nakamura N; Isono A; Toyota H; Arai H; Saito K
Am J Gastroenterol; 2017 Nov; 112(11):1636. PubMed ID: 29109487
[No Abstract] [Full Text] [Related]
10. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
[No Abstract] [Full Text] [Related]
11. Cholangitis caused by biliary hydatidosis.
Guarner-Argente C; Gomez-Oliva C; Poca M; Sainz S; Marinello FG; Villanueva C; Guarner C
Gastrointest Endosc; 2010 Dec; 72(6):1264-5; discussion 1266. PubMed ID: 20630516
[No Abstract] [Full Text] [Related]
12. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.
Gelsomino F; Vitale G; Ardizzoni A
Invest New Drugs; 2018 Feb; 36(1):144-146. PubMed ID: 28631096
[TBL] [Abstract][Full Text] [Related]
13. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
14. Peroral transhepatic cholangioscopy and antegrade sphincterotomy via EUS-guided anastomosis.
Sanchez-Ocaña R; Peñas-Herrero I; de la Serna-Higuera C; Perez-Miranda M
Gastrointest Endosc; 2016 Feb; 83(2):466-7. PubMed ID: 26348547
[No Abstract] [Full Text] [Related]
15. Nivolumab-induced neuralgic amyotrophy with hourglass-like constriction of the anterior interosseous nerve.
Porambo ME; Sedarsky KE; Elliott EJ; Theeler BJ; Smith JK
Muscle Nerve; 2019 Jun; 59(6):E40-E42. PubMed ID: 30809822
[No Abstract] [Full Text] [Related]
16. Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma.
Shikano K; Kaneko K; Kaburaki K; Isobe K; Kawabe K; Homma S; Kawai S; Nanki T
Scand J Rheumatol; 2020 Jan; 49(1):82-83. PubMed ID: 31135242
[No Abstract] [Full Text] [Related]
17. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
18. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
19. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
20. Pericardial effusion under nivolumab: case-reports and review of the literature.
Saade A; Mansuet-Lupo A; Arrondeau J; Thibault C; Mirabel M; Goldwasser F; Oudard S; Weiss L
J Immunother Cancer; 2019 Oct; 7(1):266. PubMed ID: 31627742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
